KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Emergent BioSolutions (EBS) Amortization - Deferred Charges (2016 - 2017)

Emergent BioSolutions' Amortization - Deferred Charges history spans 3 years, with the latest figure at $95000.0 for Q4 2017.

  • For Q4 2017, Amortization - Deferred Charges fell 55.19% year-over-year to $95000.0; the TTM value through Dec 2017 reached $680000.0, up 11.48%, while the annual FY2017 figure was $681000.0, 12.8% down from the prior year.
  • Amortization - Deferred Charges reached $95000.0 in Q4 2017 per EBS's latest filing, down from $195000.0 in the prior quarter.
  • In the past five years, Amortization - Deferred Charges ranged from a high of $215000.0 in Q3 2015 to a low of $95000.0 in Q4 2017.
  • Average Amortization - Deferred Charges over 3 years is $189111.1, with a median of $195000.0 recorded in 2017.
  • Peak YoY movement for Amortization - Deferred Charges: rose 7.61% in 2016, then tumbled 55.19% in 2017.
  • A 3-year view of Amortization - Deferred Charges shows it stood at $197000.0 in 2015, then increased by 7.61% to $212000.0 in 2016, then plummeted by 55.19% to $95000.0 in 2017.
  • Per Business Quant, the three most recent readings for EBS's Amortization - Deferred Charges are $95000.0 (Q4 2017), $195000.0 (Q3 2017), and $195000.0 (Q2 2017).